Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 4/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2481218 | 0.82 | DRD2 (0.56) | KDM4EALDH1A1SMN1; SMN2TSHRCYP2D6 | |
| SCHEMBL9189173 | 0.79 | MAPT (0.45) | CNR2PRKDCMAPTKDM4ENPC1 | |
| SCHEMBL3543964 | 0.78 | LMNA (0.41) | CNR2PRKDCAKR1C3MAPTKDM4E | |
| SCHEMBL3541165 | 0.76 | CNR2 (0.45) | CNR2AKR1C3MAPTNPC1RAB9A | |
| SCHEMBL28757513 | 0.75 | LMNA (0.41) | PRKDCMAPTKDM4ENPC1RAB9A | |
| SCHEMBL3543532 | 0.75 | ALDH1A1 (0.44) | CNR2PRKDCMAPTKDM4ENPC1 | |
| SCHEMBL3545303 | 0.75 | LMNA (0.41) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL10336535 | 0.74 | NPY2R (0.51) | ALDH1A1LMNASMN1; SMN2CYP2D6MEN1 | |
| SCHEMBL3173622 | 0.73 | AKR1C3 (0.70) | PRKDCAKR1C3MAPTKDM4EALDH1A1 | |
| SCHEMBL12527300 | 0.71 | AKR1C3 (0.68) | PRKDCAKR1C3MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115617-B2 | Amino-substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2006-10-03 | — | — | US | claimed |
| EP-1418916-A1 | 2-AMINO-4-HETEROARYLAMINOPYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Amgen Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| US-20030125346-A1 | Amino-substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | claimed |
| WO-2003018022-A1 | 2-AMINO-4-HETEROARYLAMINOPYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AMGEN INC. (US) | 2003-03-06 | — | — | WO | claimed |
| CN-101421234-A | Is suitable for treating p-hydroxytryptamine 5HT6Heterocyclic aryl sulfones of receptor-modulated responsive disorders | ABBOTT GMBH (DE) | 2009-04-29 | — | — | CN | disclosed |
| US-7115617-B2 | Amino-substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1418916-A1 | 2-AMINO-4-HETEROARYLAMINOPYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Amgen Inc. (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030125346-A1 | Amino-substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2003018022-A1 | 2-AMINO-4-HETEROARYLAMINOPYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AMGEN INC. (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125346-A1 | Amino-substituted pyrimidinyl derivatives and methods of use | TYMP, DPYD, TPMT | CNR2 1043/4885PRKDC 1482/4885AKR1C3 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.